MethylGene And EnVivo Pharmaceuticals, Inc. Form Collaboration With CHDI, Inc., In Support Of HDAC Program For Huntington's Disease

MONTREAL and WATERTOWN, MA and LOS ANGELES, CA -- (MARKET WIRE) -- November 16, 2006 -- MethylGene Inc. (TSX: MYG) with its collaborator EnVivo Pharmaceuticals, today announced that they have entered into a collaborative agreement with CHDI, Inc., a non-profit organization that is pursuing biotechnology approaches to rapidly discover and develop treatments for Huntington's disease (HD). In this collaboration, CHDI will provide financial and preclinical research support to MethylGene to enhance the collaboration between MethylGene and EnVivo Pharmaceuticals to progress histone deacetylase (HDAC) inhibitors for the treatment of HD. MethylGene and EnVivo formed a collaboration in February, 2005 focused on MethylGene's HDAC technology for use in neurodegenerative diseases.